Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Share News (HCM)

Share Price Information for Hutchmed (HCM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 293.00
Bid: 290.00
Ask: 293.00
Change: -3.00 (-1.01%)
Spread: 3.00 (1.034%)
Open: 286.00
High: 293.00
Low: 284.00
Prev. Close: 296.00
HCM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: musicMagpie sells on new platform; Hutchmed down

Mon, 25th Apr 2022 10:45

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.

----------

AIM - WINNERS

----------

Panther Securities PLC, up 24% at 340.00 pence, 12-month range 205.00p-350.00p. The London-based property investment company says revenue in 2021 rises 0.9% annually to GBP13.2 million from GBP13.1 million in 2020. Pretax profit jumps to GBP15.9 million from GBP2.6 million. Net asset value per share increases 13% to 553p at the end of 2021, from 488p a year earlier. Panther Securities maintains its annual dividend at 12p per share.

----------

musicMagpie PLC, up 12% at 53.00 pence, 12-month range 40.00p-200.00p. The Stockport, England-based used technology reseller says it has landed a deal to sell consumer electronics on Back Market, an online marketplace dedicated to selling refurbished devices. "The launch of musicMagpie's products will occur on the Back Market UK marketplace by the end of this month and on the Back Market US marketplace in mid-May 2022," musicMagpie says.

----------

AIM - LOSERS

----------

Hummingbird Resources PLC, down 18% at 14.32p, 12-month range 10.55p-24.00p. First quarter output declines amid planned maintenance work. Output falls to 15,548 ounces of gold, down 32% annually from 22,781 ounces. The company has projects in Mali, Liberia and Guinea.

----------

Hutchmed (China) Ltd, down 5.8% at 245.09p, 12-month range 2.22p-248.50p. The biopharmaceutical company is hurt by its exposure to China. New Covid-19 fears from China have emerged. Lockdown worries sparked panic buying in Beijing on Monday. China is already trying to contain a wave of infections in its largest city, Shanghai, which has been almost entirely locked down for weeks. With a market capitalisation of GBP2.13 billion, Hutchmed is among the largest AIM listings.

----------

By Eric Cunha; ericcunha@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
17 Apr 2020 13:19

Hutchison China Gets US FDA Fast Track Status For Surufatinib

Hutchison China Gets US FDA Fast Track Status For Surufatinib

Read more
3 Mar 2020 14:24

Hutchison China Sees Loss Widen But Lays "Foundations" In 2019

Hutchison China Sees Loss Widen But Lays "Foundations" In 2019

Read more
25 Feb 2020 16:05

UK Earnings, Trading Statements Calendar - Next 7 Days

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
12 Feb 2020 17:27

FOCUS-Coronavirus outbreak begins to disrupt booming China drug trials

By Tamara Mathias, Roxanne Liu and Manojna MaddipatlaFeb 12 (Reuters) - The fast-spreading coronavirus is starting to disrupt testing of experimental medicines in China, posing a threat to plans by global drugmakers that have invested billions of ...

Read more
10 Feb 2020 07:36

Hutchison Chi-Med shares up on updated results from 'CALYPSO'

(Sharecast News) - Hutchison China MediTech, trading as Chi-Med, announced the availability of updated results from the phase 2 'CALYPSO' study of the savolitinib and 'Imfinzi' (durvalumab) combination in a cohort of patients with metastatic papillary renal cell carcinoma (PRCC) on Monday.

Read more
23 Jan 2020 15:06

Hutchison China Prices USD110 Million American Depositary Share Offer

Hutchison China Prices USD110 Million American Depositary Share Offer

Read more
22 Jan 2020 10:44

Hutchison China Plans USD110 Million American Depositary Share Offer

Hutchison China Plans USD110 Million American Depositary Share Offer

Read more
20 Jan 2020 16:00

Hutchison Chi-Med upbeat on progress with surufatinib

(Sharecast News) - Hutchison China MediTech, trading as Chi-Med, announced on Friday that the independent data monitoring committee of the phase 3 pivotal study of surufatinib in advanced neuroendocrine tumours - pancreatic (SANET-p) has completed a pre-planned interim analysis.

Read more
20 Jan 2020 11:37

Hutchinson China Reports Early Success Of Surufatinib Phase III Study

Hutchinson China Reports Early Success Of Surufatinib Phase III Study

Read more
13 Jan 2020 09:01

Hutchison China Starts Phase II Study For Cancer Treatment In China

Hutchison China Starts Phase II Study For Cancer Treatment In China

Read more
20 Dec 2019 15:48

Hutchison Chi-Med gets priority review for 'surufatinib' in China

(Sharecast News) - Hutchison China MediTech announced on Friday that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has granted 'Priority Review' status to its new drug application for 'surufatinib', for the treatment of patients with advanced non-pancreatic neuroendocrine tumours.

Read more
20 Dec 2019 12:10

Hutchison China Hails "Positive Step" For Cancer Treatment In China

Hutchison China Hails "Positive Step" For Cancer Treatment In China

Read more
28 Nov 2019 14:58

Hutchison China MediTech's Cancer Treatment Joins Key China State List

Hutchison China MediTech's Cancer Treatment Joins Key China State List

Read more
25 Nov 2019 13:47

Hutchison China MediTech Gets Orphan Designation For Surufatinib

Hutchison China MediTech Gets Orphan Designation For Surufatinib

Read more
12 Nov 2019 12:19

CORRECT (Nov 11): Hutchison's Surufatinib Gets Acceptance For Review

CORRECT (Nov 11): Hutchison's Surufatinib Gets Acceptance For Review

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.